Plain-English translation of NCT05558501 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a treatment called mild intermittent hypoxia (MIH) — carefully controlled brief periods of breathing lower-oxygen air in a lab setting — to see if it can help people with obstructive sleep apnea improve their blood pressure, blood vessel function, and exercise ability. The researchers believe this treatment might work better than current options, especially for patients who don't tolerate or stick with standard sleep apnea machines (CPAP). You would receive either the real treatment or a placebo (room air) during lab visits over several weeks.
Many people with sleep apnea don't respond well to standard CPAP machines, either because they can't use them regularly or because the machines don't improve their other health problems like high blood pressure. This trial is exploring whether this new treatment approach could directly address these underlying health issues and offer a better option for veterans struggling with sleep apnea and related conditions.
You likely qualify if…
You likely don't qualify if…
You would visit the laboratory to breathe specially controlled air — either the mild low-oxygen mixture or regular room air — while your heart, blood pressure, and blood vessel function are monitored. The sessions would happen over several weeks, and researchers would track changes in your blood pressure, exercise capacity, and fatigue levels. Blood samples and tests would help measure improvements in your metabolism and heart health.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States